Scholarlink

Introduction <p>Inflammatory bowel disease (IBD) is a chronic, immune-mediated gastrointestinal disorder comprised of Crohn's disease (CD) and ulcerative colitis (UC). Real-world data on racial differences in disease burden, treatment patterns, and healthcare resource utilization (HCRU) remain limited.</p> Methods <p>The retrospective observational study was conducted using Optum’s de-identified Clinformatics<sup>®</sup> Data Mart Database (Optum<sup>®</sup> CDM) in the US. Data from adult patients with a diagnosis of CD and/or UC between January 1, 2010, and September 30, 2022, were extracted and analyzed to assess the prevalence of IBD, complicated/penetrating CD, and extraintestinal manifestations (EIMs) across different races/ethnicities in the US. The treatment use, HCRU, and symptomatic and psychosocial burden among patients pre-and post-IBD diagnosis were also assessed among patients stratified by race/ethnicity.</p> Results <p>A total of 271,059 patients included in the analysis were predominantly White (76.6%) followed by Black (7.9%), Hispanic (6.1%), and Asian (2.6%). IBD prevalence rose from 0.5% (2010) to 2.2% (2022). In 2022, prevalence was highest among White (2.5%) followed by Black (1.9%), Asian (1.4%), and Hispanic individuals (1.3%). Among patients with CD and UC, respectively, EIM prevalence rose from 38.4% and 31.5% in 2016 to 57.5% and 43.2% in 2022. Corticosteroids and biologics were prescribed to 38.8% and 52.8% of patients with CD and UC post-diagnosis, respectively. IBD-related HCRU increased after diagnosis, particularly among acute care patients, and was highest in Black individuals.</p> Conclusion <p>The results highlight an increased prevalence of IBD among patients from different racial and ethnic backgrounds. The study further provides insights into the IBD-related outcomes, treatment use, and HCRU patterns among diverse racial and ethnic groups and underlines the present unmet need for further research.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Racial and Ethnic Patterns Observed in Inflammatory Bowel Disease Prevalence, Clinical Burden, and Healthcare Resource Utilization in the United States: Findings from an Administrative Claims Database

  • 期刊论文

  • 发表日期：

    2026年7月9日

查看全文
  • Aarti A. Patel,
  • Shannon Ferrante,
  • Myrlene Sanon,
  • Sumesh Kachroo

摘要

Introduction

Inflammatory bowel disease (IBD) is a chronic, immune-mediated gastrointestinal disorder comprised of Crohn's disease (CD) and ulcerative colitis (UC). Real-world data on racial differences in disease burden, treatment patterns, and healthcare resource utilization (HCRU) remain limited.

Methods

The retrospective observational study was conducted using Optum’s de-identified Clinformatics® Data Mart Database (Optum® CDM) in the US. Data from adult patients with a diagnosis of CD and/or UC between January 1, 2010, and September 30, 2022, were extracted and analyzed to assess the prevalence of IBD, complicated/penetrating CD, and extraintestinal manifestations (EIMs) across different races/ethnicities in the US. The treatment use, HCRU, and symptomatic and psychosocial burden among patients pre-and post-IBD diagnosis were also assessed among patients stratified by race/ethnicity.

Results

A total of 271,059 patients included in the analysis were predominantly White (76.6%) followed by Black (7.9%), Hispanic (6.1%), and Asian (2.6%). IBD prevalence rose from 0.5% (2010) to 2.2% (2022). In 2022, prevalence was highest among White (2.5%) followed by Black (1.9%), Asian (1.4%), and Hispanic individuals (1.3%). Among patients with CD and UC, respectively, EIM prevalence rose from 38.4% and 31.5% in 2016 to 57.5% and 43.2% in 2022. Corticosteroids and biologics were prescribed to 38.8% and 52.8% of patients with CD and UC post-diagnosis, respectively. IBD-related HCRU increased after diagnosis, particularly among acute care patients, and was highest in Black individuals.

Conclusion

The results highlight an increased prevalence of IBD among patients from different racial and ethnic backgrounds. The study further provides insights into the IBD-related outcomes, treatment use, and HCRU patterns among diverse racial and ethnic groups and underlines the present unmet need for further research.